06/04/2026
Sweden and the Netherlands are taking an important step forward in cancer care by advancing the routine clinical use of Whole Genome Sequencing (WGS) for cancer patients.
This agreement between Genomic Medicine Sweden and the Hartwig Medical Foundation represents more than a collaboration between two respected organizations. It provides a real roadmap for how governments, healthcare systems, and medical institutions can bring deeper genomic insight into standard cancer care.
At SpeciCare, we strongly support this direction.
We believe patients deserve access to the most advanced testing available, including deep genomic sequencing, treatment effectiveness testing, clinical trial matching, and other precision medicine tools that may help guide better treatment decisions.
That is why we advocate for cryopreserving biopsy and tumor tissue whenever possible. Properly preserved tissue can help protect future testing options and give patients, physicians, and researchers more opportunities to learn from each patient’s unique cancer biology.
SpeciCare applauds Sweden, the Netherlands, Genomic Medicine Sweden, and the Hartwig Medical Foundation for helping move cancer care toward a more personalized, data-driven future.
This is the direction cancer care should be heading worldwide.
(Full release in comments)
